Request Demo

Last update 08 May 2025

RHM Klinik & Altenheimbetriebe B.V. & Co. Kg

Dissolved

| Private Company|2003|Germany|

www.rhm-kliniken.de

Dissolved

| Private Company|2003|Germany|

www.rhm-kliniken.de

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with RHM Klinik & Altenheimbetriebe B.V. & Co. Kg

0 Patents (Medical) associated with RHM Klinik & Altenheimbetriebe B.V. & Co. Kg

Literatures (Medical) associated with RHM Klinik & Altenheimbetriebe B.V. & Co. Kg

01 Feb 2016·Zeitschrift für Rheumatologie

DGRh-Empfehlungen zur Implementierung aktueller Sicherheitsaspekte in die NSAR-Therapie muskuloskelettaler Schmerzen

Review

Author: W W Bolten ; K Krüger ; D O Stichtenoth ; Kommission Pharmakotherapie der DGRh ; S Reiter-Niesert

NSAIDs exert their anti-inflammatory and analgesic effects by inhibition of COX‑2, a key enzyme for proinflammatory prostanoid synthesis. Therapy with NSAIDs is limited by their typical gastrointestinal, cardiovascular and renal side effects, which are caused by inhibition of COX‑1 (gastrointestinal toxicity), COX‑2 (cardiovascular side effects) or both COX-isoenzymes (renal side effects). Appropriate prevention strategies should be employed in patients at risk. If gastrointestinal risk factors are present, co-administration of a proton pump inhibitor or misoprostol is recommended; in patients with cardiovascular risk, coxibs, diclofenac and high-dose ibuprofen should be avoided. Furthermore, drug interactions and contraindications should be considered. In patients with renal impairment (GFR < 30 ml/min) all NSAIDs must be avoided. Ulcer anamnesis is a contraindication for traditional NSAIDs. Preexisting cardio- or cerebrovascular diseases are contraindications for coxibs. Treatment decisions should be individually based with a continuous monitoring of the risk - benefit ratio and exploitation of non-pharmacological treatment options.

01 Nov 2012·Zeitschrift für RheumatologieQ4 · MEDICINE

Empfehlungen zur symptomatischen Therapie mit Opioidanalgetika bei rheumatischen Schmerzen

Q4 · MEDICINE

Article

Author: und die Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie ; W.W. Bolten ; S. Reiter

The treatment of musculoskeletal pain is often difficult. For this reason opioids are increasingly being used for chronic musculoskeletal complaints despite poor or lacking evidence for their pain relieving and function improving effects. However, side effects are common and can be severe. Opioid-induced hyperalgesia can lead to higher doses and stronger pain and increase the risk of side effects. Long-term treatment of rheumatic pain with opioids should be carried out with caution.

Rheumatic diseases

Author: Bolten, W. W.

A review on rheumatic diseases (arthritis, gout, rheumatism), limits in causal treatment of rheumatism, and recommendations of therapy.Pathophysiol. and clinics, and therapy of arthritis and rheumatoid arthritis by micronutrients (vitamin C, vitamin E, carotenes, glucosamine sulfate, antioxidants) are discussed.

100 Deals associated with RHM Klinik & Altenheimbetriebe B.V. & Co. Kg

100 Translational Medicine associated with RHM Klinik & Altenheimbetriebe B.V. & Co. Kg

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 06 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

RHM Klinik & Altenheimbetriebe B.V. & Co. Kg

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 06 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing